Schulte Fiona, Russell K Brooke, Cullen Patricia, Embry Leanne, Fay-McClymont Taryn, Johnston Donna, Rosenberg Abby R, Sung Lillian
Departments of Oncology and Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Haematology, Oncology and Transplant Program, Alberta Children's Hospital Research Institute, Alberta Children's Hospital, Calgary, Alberta, Canada.
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26442. Epub 2017 Mar 7.
Pediatric central nervous system (CNS) tumor survivors are at high risk for numerous late effects including decreased health-related quality of life (HRQOL). Our objective was to summarize studies describing HRQOL in pediatric CNS tumor survivors and compare HRQOL outcomes in studies that included a comparison group.
EMBASE, MEDLINE, and PsychINFO were used to identify relevant articles published until August, 2016. Eligible studies reported outcomes for pediatric CNS tumor survivors diagnosed before age 21, at least 5 years from diagnosis and/or 2 years off therapy and used a standardized measure of HRQOL. All data were abstracted by two reviewers. Random-effects meta-analyses were performed using Review Manager 5.0.
Of 1,912 unique articles identified, 74 were included in this review. Papers described 29 different HRQOL tools. Meta-analyses compared pediatric CNS tumor survivors to healthy comparisons and other pediatric cancer survivors separately. HRQOL was significantly lower for CNS (n = 797) than healthy comparisons (n = 1,397) (mean difference = -0.54, 95% confidence interval [CI] = -0.72 to -0.35, P < 0.001, I = 35%). HRQOL was also significantly lower for CNS (n = 244) than non-CNS survivors (n = 414) (mean difference = -0.56, 95% CI = -0.73 to -0.38, P < 0.00001, I = 0%).
Pediatric CNS tumor survivors experience worse HRQOL than healthy comparisons and non-CNS cancer survivors. Future HRQOL work should be longitudinal, and/or multisite studies that examine HRQOL by diagnosis and treatment modalities.
小儿中枢神经系统(CNS)肿瘤幸存者面临多种晚期效应的高风险,包括健康相关生活质量(HRQOL)下降。我们的目的是总结描述小儿CNS肿瘤幸存者HRQOL的研究,并比较包含对照组的研究中的HRQOL结果。
使用EMBASE、MEDLINE和PsychINFO来识别截至2016年8月发表的相关文章。符合条件的研究报告了21岁前诊断的小儿CNS肿瘤幸存者的结果,诊断后至少5年和/或停止治疗2年后,并使用了HRQOL的标准化测量方法。所有数据由两名审阅者提取。使用Review Manager 5.0进行随机效应荟萃分析。
在识别出的1912篇独特文章中,74篇纳入了本综述。论文描述了29种不同的HRQOL工具。荟萃分析分别将小儿CNS肿瘤幸存者与健康对照者和其他小儿癌症幸存者进行了比较。CNS组(n = 797)的HRQOL显著低于健康对照者(n = 1397)(平均差异=-0.54,95%置信区间[CI]=-0.72至-0.35,P<0.001,I=35%)。CNS组(n = 244)的HRQOL也显著低于非CNS幸存者(n = 414)(平均差异=-0.56,95%CI=-0.73至-0.38,P<0.00001,I=0%)。
小儿CNS肿瘤幸存者的HRQOL比健康对照者和非CNS癌症幸存者更差。未来关于HRQOL的工作应该是纵向的,和/或通过诊断和治疗方式检查HRQOL的多中心研究。